CD93 or use of soluble fragment thereof

Patent metadata

Field	Value
Publication number	US-8993343-B2
Application number	US-201013146876-A
Country	US
Kind code	B2
Filing date	Jan 18, 2010
Priority date	Jan 28, 2009
Publication date	Mar 31, 2015
Grant date	Mar 31, 2015

Abstract

The present invention relates to an anti-inflammatory composition using the antibody specifically binding to CD93 or its soluble fragment, and a diagnostic method and a diagnostic kit for inflammatory disease using CD93 or its soluble fragment specific antibody or aptamer.

First claim

What is claimed is:

1. A method for diagnosing rheumatoid arthritis comprising:
coating proteins from a biological sample obtained from synovial fluid and a control on a fixture;
inducing an antigen-antibody reaction by adding an antibody specifically binding to a CD93 soluble fragment to the above fixture;
detecting the antigen-antibody reaction product produced by the above antigen-antibody reaction by using a secondary antibody conjugate marker and chromogenic substrate solution;
comparing the detection results between the biological sample and the control; and
diagnosing rheumatoid arthritis or high risk of rheumatoid arthritis when CD93 soluble fragment is up-regulated in the biological sample, compared with the level in the control,
wherein the antigen-antibody reaction product is measured by a sandwich ELISA.

2. The method according to claim 1 , wherein the fixture is selected from the group consisting of nitrocellulose membrane, PVDF membrane (polyvinylidene difluoride membrane), 96-well plate made of polyvinyl resin or polystylene resin, and glass side glass.

3. The method according to claim 1 , wherein the secondary antibody conjugate marker is selected from the group consisting of HRP (horseradish peroxidase), alkaline phosphatase, colloid gold, FITC (poly L-lysine-fluorescein isothiocyanate), RITC (rhodamine-B-isothiocyanate), and dye.

4. The method according to claim 1 , wherein the chromogenic substrate solution is the one selected from the group consisting of TMB (3,3′,5,5′-tetramethyl bezidine), ABTS [2,2′-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid)], and OPD (o-phenylenediamine).

5. The method according to claim 1 , wherein the soluble fragment is the 95 kDa ectodomain of CD93 protein released after cell culture.

6. The method according to claim 1 , wherein the soluble fragment has the amino acid sequence of SEQ ID NO:1.

Assignees

• Park Young Woo
• Jeon Jae Won
• Jung Joon-Goo
• Choi Hye In
• Sohn Myung-Ho
• Kim Ho Youn
• Cho Mi-La
• Jang Young-Soon
• Moon Ji-Hun
• Park Ji Hyun
• Korea Res Inst Of Bioscience

Inventors

• Park Young Woo
• Jeon Jae Won
• Jung Joon-Goo
• Choi Hye In
• Sohn Myung-Ho
• Kim Ho Youn
• Cho Mi-La
• Jang Young-Soon
• Moon Ji-Hun
• Park Ji Hyun

Classifications

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61P37/08

  Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14) · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P31/12

  Antivirals · CPC title

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title